NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $128,000 | -79.0% | 23,755 | -47.4% | 0.00% | -75.0% |
| Q4 2021 | $610,000 | -29.6% | 45,155 | -6.3% | 0.01% | -38.5% |
| Q3 2021 | $866,000 | +30.8% | 48,205 | +24.9% | 0.01% | +30.0% |
| Q2 2021 | $662,000 | -25.6% | 38,605 | -13.3% | 0.01% | -28.6% |
| Q1 2021 | $890,000 | -55.8% | 44,505 | -62.4% | 0.01% | -58.8% |
| Q4 2020 | $2,013,000 | +1.4% | 118,405 | -1.1% | 0.03% | -10.5% |
| Q3 2020 | $1,986,000 | -35.9% | 119,700 | -10.6% | 0.04% | -41.5% |
| Q2 2020 | $3,100,000 | -1.5% | 133,850 | -24.1% | 0.06% | -16.7% |
| Q1 2020 | $3,146,000 | -21.3% | 176,250 | -4.8% | 0.08% | +32.2% |
| Q4 2019 | $3,996,000 | +5.2% | 185,110 | -11.2% | 0.06% | +13.5% |
| Q3 2019 | $3,798,000 | -43.4% | 208,485 | +10.5% | 0.05% | -40.2% |
| Q2 2019 | $6,711,000 | -14.7% | 188,631 | -19.5% | 0.09% | -17.1% |
| Q1 2019 | $7,872,000 | -24.1% | 234,281 | -25.7% | 0.10% | -32.3% |
| Q4 2018 | $10,368,000 | -17.9% | 315,431 | +52.3% | 0.16% | -2.5% |
| Q3 2018 | $12,623,000 | +68.6% | 207,076 | +35.1% | 0.16% | +67.4% |
| Q2 2018 | $7,485,000 | -10.6% | 153,291 | +94.5% | 0.10% | -11.2% |
| Q1 2018 | $8,373,000 | -54.5% | 78,796 | -74.4% | 0.11% | -48.8% |
| Q4 2017 | $18,397,000 | +203.9% | 308,062 | +22.1% | 0.21% | +198.6% |
| Q3 2017 | $6,053,000 | +33.2% | 252,202 | +8.5% | 0.07% | +27.3% |
| Q2 2017 | $4,543,000 | -17.4% | 232,402 | -0.9% | 0.06% | -17.9% |
| Q1 2017 | $5,501,000 | +123.5% | 234,402 | +16.9% | 0.07% | +116.1% |
| Q4 2016 | $2,461,000 | +111.2% | 200,552 | +195.8% | 0.03% | +121.4% |
| Q3 2016 | $1,165,000 | -69.6% | 67,800 | -74.8% | 0.01% | -41.7% |
| Q2 2016 | $3,834,000 | +100.6% | 269,400 | +93.9% | 0.02% | -4.0% |
| Q1 2016 | $1,911,000 | -11.2% | 138,950 | +8.9% | 0.02% | -13.8% |
| Q4 2015 | $2,151,000 | +109.4% | 127,650 | +36.2% | 0.03% | +107.1% |
| Q3 2015 | $1,027,000 | -56.2% | 93,700 | -50.0% | 0.01% | -50.0% |
| Q2 2015 | $2,343,000 | +8.2% | 187,300 | -4.9% | 0.03% | +12.0% |
| Q1 2015 | $2,166,000 | +72.7% | 196,900 | +143.4% | 0.02% | +92.3% |
| Q4 2014 | $1,254,000 | +29.4% | 80,900 | +0.7% | 0.01% | +18.2% |
| Q3 2014 | $969,000 | +45.3% | 80,300 | +54.4% | 0.01% | +83.3% |
| Q2 2014 | $667,000 | +22.4% | 52,000 | +15.6% | 0.01% | -14.3% |
| Q1 2014 | $545,000 | +20.0% | 45,000 | +12.5% | 0.01% | +16.7% |
| Q4 2013 | $454,000 | +24.0% | 40,000 | +14.3% | 0.01% | +20.0% |
| Q3 2013 | $366,000 | -9.4% | 35,000 | 0.0% | 0.01% | 0.0% |
| Q2 2013 | $404,000 | – | 35,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |